Immunotherapy A new frontier Candace S. Johnson, PhD Immunotherapy - PowerPoint PPT Presentation

Immunotherapy “A new frontier” Candace S. Johnson, PhD

Immunotherapy is the new focus in oncology

Tipping point for cancer immunotherapy • Major advances in the last 10 years – Your immune system protects you against cancer – Success with vaccination against HPV (Gardasil) – Knowledge of the immune system has increased

The Immune System

Roswell Park Study: Immune responses in ovarian cancer = improved survival 1.0 Intraepithelial CD8+ TIL lowest tertile 0.8 Cumulative Survival all others 0.6 0.4 0.2 Log Rank test P=0.009 0.0 0 20 40 60 80 100 120 140 Overall Survival (Months) Median survival: 55 vs. 26 months Sato et al , PNAS, 2005, 102:18538

Immunotherapy – “living drug” not chemicals, a targeted answer to cancer: Immune cell Tumor cell (T cell) boosts your immune system to help eliminate cancer cells enhances immune response by providing additional components http://www.theanswertocancer.org/

Cancer Immunotherapy • Major advances recently – Several FDA approvals for a class of immunotherapies – “immune checkpoint blockers”. – Now approved for melanoma, lung, bladder, liver, kidney: and the list continues to grow.

Immunotherapy at RPCI: Leading the way monoclonal antibodies oncolytic virus checkpoint blockade adoptive T cell transfer cytokine/immunomodulator cancer vaccine Not all immunotherapies are created equal • • Which is the best immunotherapy for me? • Advanced next generation http://www.theanswertocancer.org/

Benefits of cancer immunotherapy Power to target cancer in a specific way Ability to work on many types of cancer even those that do not respond to chemo or radiation Potential for reduced side effects commonly associated with chemotherapy e.g. nausea, vomiting, hair loss Possibility for long-term remissions http://www.theanswertocancer.org/

Selection of trials conducted at Roswell Park: No cancer type is left behind breast colon leukemia lung ovarian prostate cancer cancer lymphoma cancer melanoma cancer cancer I 243813 I 243813 PH 236713 I 243813 I 243813 I 243813 I 243813 checkpoint LUD2014-011 LUD2014-011 LUD2014-011 LUD2014-011 LUD2014-011 LUD2014-011 PH 281816 blockade PH 253914 I 274515 PH 269015 PH 227012 I 276015 PH 283216 I 288216 I 258514 I 258514 PH 251514 I 258514 I 258514 I 258514 I 258514 adoptive I 210611 I 230612 I 223912 transfer PH 268215 I 283616 I 191511 I 191511 I 227712 I 191511 I 215912 I 248613 I 250113 cancer I 277115 vaccines LUD2015-001 LUD2015-001 PH 280416 oncolytic virus

Next generation immunotherapies at Roswell Park: Generating T cells for adoptive transfer therapy receptor transfer TCR CAR TCR = T cell receptor recognize and destroy tumor cells CAR = chimeric antigen receptor

Recent FDA approval for first engineered T cell

Our expectations of clinical outcomes of immunotherapy 100% immunotherapies in combination % of treated patients alive immunotherapies traditional therapies 0% Time Traditional therapies: Immunotherapies: Lives extended, but responses often not durable. Disease progresses or recurs. Patients with sufficient anti-cancer immunity achieve durable disease control. Few lives ultimately saved. Many lives are saved.